Prognostic significance of minimal residual disease detection and PML/RAR-α isoform type: Long-term follow-up in acute promyelocytic leukemia

Blood

Volumn 98, Issue 9, 2001, Pages 2651-2656

  Jurcic, Joseph G ^a,b,c   Nimer, Stephen D ^a   Scheinberg, David A ^b   Deblasio, Tony ^c   Warrell Jr , Raymond P ^a   Miller Jr , Wilson H ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; CYTARABINE; IDARUBICIN; IODINE 131; MESSENGER RNA; MONOCLONAL ANTIBODY M 195; RECEPTOR SUBTYPE; RETINOIC ACID; RETINOIC ACID RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CHILD; DNA STRAND BREAKAGE; FOLLOW UP; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0035525767     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.9.2651     Document Type: Article

References (49)

1. de Thé H, Chomienne C, Lanotte M, Degos L, Déjean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature. 1990;347:558-561.
2. Miller WH Jr, Warrell RP Jr, Frankel SR, et al. Novel retinoic acid receptor-α transcripts in acute promyelocytic leukemia responsive to all-trans retinoic acid. J Natl Cancer Inst. 1990;32:1932-1933.
3. Kakizuka A, Miller WH Jr, Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR-α with a novel putative transcription factor, PML. Cell. 1991;66:663-674.
4. de Thé H, Lavau C, Marcio A, Chomienne C, Degos L, Déjean A. The PML-RAR-α fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 1991;66:675-684.
5. Huang ME, Ye YC, Chen SR, et al. Use of all trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567-572.
6. Castaigne S, Chomienne C, Daniel MT, Berger R, Fenaux P, Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia; I: clinical results. Blood. 1990;76:1704-1709.
7. Warren RP Jr, Frankel SR, Miller WH Jr, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic add). N Engl J Med. 1991;324:1385-1393.
8. Tallman MS, Anderson JW, Schiffer CA, et al. Alltrans retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021-1028.
9. Biondi A, Rambaldi A, Alcalay M, et al. RAR-α rearrangements as a genetic marker for diagnosis and monitoring in acute promyelocytic leukemia. Blood. 1991;77:1418-1422.
10. Miller WH Jr, Kakizuka A, Frankel SR, et al. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor-α clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 1992;89:2694-2698.
11. Castaigne S, Balitrand N, de Thé H, Déjean A, Degos L, Chomienne C. A PML/retinoic acid receptor-α fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood. 1992;79:3110-3115.
12. Borrow J, Goddard AD, Gibbons B, et al. Diagnosis of acute promyelocytic leukaemia by RT-PCR: detection of PML-RARA and RAR-PML fusion transcripts. Br J Haematol. 1992;82:529-540.
13. LoCoco F, Diverio D, Pandolfi PP, et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia. Lancet. 1992;340:1437-1438.
14. Miller WH Jr, Levine K, DeBlasio A, Frankel SR, Dmitrovsky E, Warrell RP Jr. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-α a fusion mRNA. Blood. 1993;82:1689-1694.
15. Huang W, Sun G-L, Li Z-S, et al. Acute promyelocytic leukemia: clinical relevance of two major PML-RARα isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood. 1993;82:1264-1269.
16. Diverio D, Pandofi PP, Biondi A, et al. Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission. Blood. 1993;82:3556-3559.
17. Ikeda K, Sasaki K, Tasaka T, et al. Reverse transcription-polymerase chain reaction for PML-RARα fusion transcripts in acute promyelocytic leukemia and its application to minimal residual leukemia detection. Leukemia. 1993;7:544-548.
18. Fukutani H, Naoe T, Ohno R, at al. Prognostic significance of the RT-PCR assay of PML-RARA transcripts in acute promyelocytic leukemia. Leukemia. 1995;9:588-593.
19. Takatsuki H, Umemura T, Sadamura S, et al. Detection of minimal residual disease by reverse transcriptase polymerase chain reaction for the PML/RARα fusion mRNA: a study in patients with acute promyelocytic leukemia following peripheral stem cell transplantation. Leukemia. 1995;9:889-892.
20. Pandolfi PP, Alcalay M, Fagioli M, et al. Genomic variability and alternative splicing generate multiple PML/RARα transcripts that encode aberrant PML proteins and PML/RARα isoforms in acute promyelocytic leukemia. EMBO J. 1992;11:1397-1407.
21. Biondi A, Rambaldi A, Pandofi PP, et al. Molecular monitoring of myl/RAR-α fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood. 1992;80:492-497.
22. Vahdat L, Maslak P, Miller WH Jr, et al. Early mortality and retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis lowdose chemotherapy, PML/RAR-α isoform, and CD13 expression in patients treated with all-trans retinoid acid. Blood. 1994;84:3843-3849.
23. Gallagher R, Willman CL, Slack JL, et al. Association of PML/RARα fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood. 1997;90:1656-1663.
24. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:460-462.
25. Miller WH Jr, Jakubowski A, Tong WP, et al. 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. Blood. 1995;85:3021-3027.
26. Frankel SR, Eardley A, Heller G, et al. All-transretinoic acid for acute promyelocytic leukemia: results of the New York study. Ann Intern Med. 1994;120:278-286.
27. Warrell RP Jr, Maslak P, Eardley A, Heller G, Miller WH Jr, Frankel SR. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia. 1994;8:929-933.
28. Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HUM195 in acute promyelocytic leukemia. Clin Cancer Res. 2000;6:372-380.
29. Jurcic JG, Caron PC, Miller WH Jr, et al. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. Leukemia. 1995;9:244-248.
30. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813-819.
31. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH, the MRC Adult Leukaemia Working Party. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood. 1999;93:4131-4143.
32. Sanz MA, LoCoco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247-1253.
33. Diverio D, Rossi V, Avvisati G, et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. Blood. 1998;92:784-789.
34. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood. 1997;90:1014-1021.
35. Soignet SL, Maslak P, Wang Z-G, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339:1341-1348.
36. Estey E, Giles F, Kantarjian H, et al. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94:2230-2235.
37. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all-trans retinoic acid (ATRA) following chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94:1192-1200.
38. Hughes TP, Morgan GJ, Martiat P, Goldman JM. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood. 1991;77:874-878.
39. Pignon JM, Henni T, Amselem S, et al. Frequent detection of minimal residual disease by use of the polymerase chain reaction in long-term survivors after bone marrow transplantation for chronic myeloid leukemia. Leukemia. 1990;4:83-86.
40. Delfau M-H, Kerckaert J-P, d'Hooghe MC, et al. Detection of minimal residual disease in chronic myeloid leukemia patients after bone marrow transplantation by polymerase chain reaction. Leukemia. 1989;4:1-5.
41. Mackinnon S, Barnett L, Heller G, O'Reilly RJ. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood. 1994;83:3409-3416.
42. Lee M-S, Kantarjian H, Talpaz M, et al. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood. 1992;79:1920-1923.
43. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood. 1993;82:712-715.
44. Miyamoto T, Nagafuji K, Akashi K, et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with (8;21) acute myelogenous leukemia. Blood. 1996;87:4789-4796.
45. Jurlander J, Caliguiri MA, Ruutu T, et al. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood. 1996;88:2183-2191.
46. Morschhauser F, Cayuela JM, Martini S, et al. Evaluation of minimal residual disease using reverse transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients. J Clin Oncol. 2000;18:788-794.
47. Roth MS, Antin JH, Bingham EL, Ginsburg D. Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia. Blood. 1989;74:882-885.
48. Willman CL, Yeap B, Bi W, et al. Predictive value of automated, quantitative real-time RT-PCR performed at the end of consolidation of acute promyelocytic leukemia (APL): a SWOG, CALGB, and ECOG intergroup study (INT-0129). Proc Am Soc Clin Oncol. 2000;19:5a.
49. Slack JL, Yu M. Constitutive expression of promyelocytic leukemia-associated oncogene PML-RARα in TF1 cells: isoform-specific and retinoic acid-dependent effects on growth, bcl-2 expression, and apoptosis. Blood. 1998;91:3347-3356.